1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,195 | 0,212 | 17.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. | 287 | PR Newswire | STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which... ► Artikel lesen | |
| 02.12. | VIVA BIOTECH (01873): GRANT OF SHARE OPTIONS | 5 | HKEx | ||
| 29.09. | Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry | 255 | PR Newswire | Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical... ► Artikel lesen | |
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 29.09. | Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry | 339 | PR Newswire | Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical... ► Artikel lesen | |
| 25.09. | VIVA BIOTECH (01873): INTERIM REPORT 2025 | - | HKEx | ||
| 02.09. | Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights | 243 | PR Newswire | SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge... ► Artikel lesen | |
| 28.08. | Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth | 362 | PR Newswire | Financial Highlights for Interim Results ended 30 June 2025Revenue reached RMB831.9 millionGross profit amounted to RMB339.4 millionGross profit margin was 40.8%, an increase of 6.3 percentage... ► Artikel lesen | |
| 28.08. | VIVA BIOTECH (01873): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 2 | HKEx | ||
| 18.08. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 2 | HKEx | ||
| 15.05. | Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery | 359 | PR Newswire | SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive... ► Artikel lesen | |
| 28.03. | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 395 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
| 27.03. | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 201 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,568 | +0,17 % | EILMELDUNG: Valneva unter Druck - Anleger verlieren die Nerven! | ||
| NOVONESIS | 52,98 | -0,19 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| GENMAB | 270,40 | +0,07 % | Genmab A/S: Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period | Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,880 | -1,77 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| BEONE MEDICINES LTD ADR | 264,00 | +1,54 % | RBC Kapital bestätigt "Outperform"-Rating für BeOne Medicines | ||
| SINO BIOPHARM | 0,722 | -0,47 % | SINO BIOPHARM (01177): VOLUNTARY ANNOUNCEMENT - "CULMERCICLIB CAPSULE" APPROVED FOR MARKETING | ||
| VERICEL | 30,400 | -2,56 % | Vericel Corporation: Vericel Reports Third Quarter 2025 Financial Results | Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow... ► Artikel lesen | |
| MOLECULIN BIOTECH | 4,160 | -11,30 % | Moleculin Biotech, Inc.: Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors | Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of AtlantaResults demonstrated WP1066 induces anti-tumor immune... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 8,500 | +4,29 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,314 | -2,79 % | MustGrow Biologics Corp.: MustGrow Reports Significant U.S. Potato Yield and Economic Performance in Large Scale Field Trials Utilizing TerraSante | Mustard-derived organic TerraSanteTM focuses on crop yields, soil and soil microbiome health, and nutrient/water use efficiencies;Large scale field trial showed 2 ton per acre yield increase with larger... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,590 | +3,38 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| ZAI LAB LTD ADR | 14,600 | -0,68 % | ZAI LAB (09688): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | ||
| REGENXBIO | 12,200 | +7,96 % | REGENXBIO Inc.: REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights | RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026
Pivotal trial enrollment... ► Artikel lesen | |
| AKEBIA | 1,388 | +0,87 % | Akebia Therapeutics, Inc.: Akebia Announces Establishment of Rare Kidney Disease Pipeline | Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 6,950 | 0,00 % | ZEVRA THERAPEUTICS, INC. - 8-K, Current Report |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,199 Euro und damit +1,02 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.